Detect early cognitive decline Parkinsons
- Trial ID
- NCT05025254
- Official Title
- Deep Cognitive Endophenotyping of Parkinson's Disease: A Platform Development and Pilot Study
- Goal
- Detect early cognitive decline Parkinsons
- Status
- RECRUITING
- Sponsor
- McGill University
- Study Type
- OBSERVATIONAL
- Enrollment
- 1000 participants
- Conditions
- Parkinson Disease
- Interventions
- Neurocognitive testing
Summary For Families
The goal is to create a detailed cognitive fingerprint to better identify and track the thinking and memory changes that happen in Parkinson's, and to develop sensitive tools for future research or care. The approach is observational neurocognitive testing, using paper and computer tasks that measure memory, attention, language, and problem solving to detect subtle changes earlier than routine exams; it does not test a drug and does not change your Parkinson's medications. The study is looking for people aged 45 to 90 with Parkinson's diagnosed by a neurologist, plus healthy adults with no neurological illness as controls. People with psychotic spectrum disorders, uncontrolled depression, advanced dementia needing daily help, major stroke, major head injury, or epilepsy treated with anti-seizure medications are not eligible.
Locations
- McGill University Health Centre, Montreal, Quebec, Canada
Frequently Asked Questions
- What is this trial testing?
- This trial is studying Neurocognitive testing. The goal is to create a detailed cognitive fingerprint to better identify and track the thinking and memory changes that happen in Parkinson's, and to develop sensitive tools for future research or care. The approach is observational neurocognitive testing, using paper and computer tasks that measure memory, attention, language, and problem solving to detect subtle changes earlier than routine exams; it does not test a drug and does not change your Parkinson's medications. The study is looking for people aged 45 to 90 with Parkinson's diagnosed by a neurologist, plus healthy adults with no neurological illness as controls. People with psychotic spectrum disorders, uncontrolled depression, advanced dementia needing daily help, major stroke, major head injury, or epilepsy treated with anti-seizure medications are not eligible.
- Who can participate?
- Participants must be between 45 Years and 90 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 1 year and 1 month.
- Will I get the real drug or a placebo?
- It depends on the trial design. Some Parkinson's trials are placebo controlled, meaning a portion of participants get an inactive comparison while others get the experimental treatment. Some use crossover designs so everyone eventually receives the active treatment at some point. Observational trials do not use a placebo at all because they are not testing a new treatment. The consent form for any specific trial spells out the design and your odds of being assigned to placebo before you enroll.
- How often will I need to visit the study site?
- Visit frequency varies by trial. Many Parkinson's studies require an in person visit every 4 to 12 weeks during the active treatment phase, with shorter or longer gaps depending on the design. The site coordinator can give you the full visit schedule before you sign anything, so you know what the time commitment looks like.
- Can I leave the trial if I change my mind?
- Yes. You can withdraw from any clinical trial at any time, for any reason, without affecting your standard medical care. Trials are voluntary by law. The team may ask if you are willing to do a brief exit visit so they can collect safety information, but you are not obligated.
- Will travel or parking be reimbursed?
- Many trials reimburse for parking, mileage, and sometimes lodging if the site is far from your home. Reimbursement policies vary by sponsor and site. When you contact the trial team, ask specifically what is covered and how reimbursement is processed.
- Can my spouse or care partner come with me to visits?
- In most cases yes, and it is often encouraged. Care partners can help with notes, questions, and getting home safely after a long visit. Some study assessments do need to happen one on one, but care partners are usually welcome for the rest of the appointment.